These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11768629)

  • 21. A fixed-dose, dose-response study of ropinirole prolonged release in early stage Parkinson's disease.
    Zesiewicz TA; Chriscoe S; Jimenez T; Upward J; VanMeter S
    Neurodegener Dis Manag; 2017 Feb; 7(1):49-59. PubMed ID: 28120629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
    Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE
    N Engl J Med; 2000 May; 342(20):1484-91. PubMed ID: 10816186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].
    Vaamonde J; Ibáñez R; Hernández A; Gudín M; de Luis P; del Real MA
    Neurologia; 2001 Feb; 16(2):81-4. PubMed ID: 11257935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
    Watts RL; Lyons KE; Pahwa R; Sethi K; Stern M; Hauser RA; Olanow W; Gray AM; Adams B; Earl NL;
    Mov Disord; 2010 May; 25(7):858-66. PubMed ID: 20461803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease.
    Dusek P; Busková J; Růzicka E; Majerová V; Srp A; Jech R; Roth J; Sonka K
    Clin Neuropharmacol; 2010 Jul; 33(4):186-90. PubMed ID: 20661025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
    Tompson D; Oliver-Willwong R
    Clin Neuropharmacol; 2009; 32(3):140-8. PubMed ID: 18978485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk and course of motor complications in a population-based incident Parkinson's disease cohort.
    Bjornestad A; Forsaa EB; Pedersen KF; Tysnes OB; Larsen JP; Alves G
    Parkinsonism Relat Disord; 2016 Jan; 22():48-53. PubMed ID: 26585090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa.
    Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE; Abdalla M;
    Mov Disord; 2006 Nov; 21(11):1844-50. PubMed ID: 16958094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
    Reichmann H; Boas J; Macmahon D; Myllyla V; Hakala A; Reinikainen K;
    Acta Neurol Scand; 2005 Jan; 111(1):21-8. PubMed ID: 15595934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.
    Alvarez L; Macias R; Lopez G; Alvarez E; Pavon N; Rodriguez-Oroz MC; Juncos JL; Maragoto C; Guridi J; Litvan I; Tolosa ES; Koller W; Vitek J; DeLong MR; Obeso JA
    Brain; 2005 Mar; 128(Pt 3):570-83. PubMed ID: 15689366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease.
    Iansek R; Danoudis M
    Parkinsonism Relat Disord; 2011 Aug; 17(7):533-6. PubMed ID: 21576031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
    Hauser RA; McDermott MP; Messing S
    Arch Neurol; 2006 Dec; 63(12):1756-60. PubMed ID: 17172616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ropinirole for the treatment of tremor in early Parkinson's disease.
    Schrag A; Keens J; Warner J;
    Eur J Neurol; 2002 May; 9(3):253-7. PubMed ID: 11985633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ropinirole in the symptomatic treatment of Parkinson's disease.
    Brooks DJ; Torjanski N; Burn DJ
    J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease.
    Pinter MM; Rutgers AW; Hebenstreit E
    J Neural Transm (Vienna); 2000; 107(11):1307-23. PubMed ID: 11145006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
    Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
    Antonini A; Isaias IU; Canesi M; Zibetti M; Mancini F; Manfredi L; Dal Fante M; Lopiano L; Pezzoli G
    Mov Disord; 2007 Jun; 22(8):1145-9. PubMed ID: 17661426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study.
    Zhang Z; Wang J; Zhang X; Chen S; Wang Z; Zhang B; Liu C; Qu Q; Cheng Y; Li J; Cao H; Cai M; Zhu R
    Parkinsonism Relat Disord; 2013 Nov; 19(11):1022-6. PubMed ID: 23932066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.